Late-stage clinical biopharmaceutical company Definium Therapeutics Inc (Nasdaq:DFTX) on Wednesday reported positive topline results from its Phase 3 Voyage study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 micrograms in adults with generalised anxiety disorder (GAD).
The study met its primary and all key secondary efficacy endpoints, with DT120 ODT producing a placebo-adjusted improvement of 5.4 points in the Hamilton Anxiety Rating Scale score at Week 12 (p
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART